RECRUITING

Imaging Studies in Corticobasal Syndrome

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The primary goal of this study is to investigate inflammation and white matter damage in corticobasal syndrome and determine whether these processes are related to each other. The investigator's will address our goal by using neuroimaging and blood plasma biomarkers, as well as molecular pathology.

Official Title

Neuroinflammation, White Matter Integrity, AD Biomarkers and Pathology in Corticobasal Syndrome

Quick Facts

Study Start:2025-06-01
Study Completion:2031-03-30
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT07000851

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Age 18 years or older
  2. * Meet possible or probable CBS criteria
  1. * Subjects will be excluded if MRI is contraindicated (due to implanted device, severe claustrophobia, etc)
  2. * Subjects will be excluded if they have a concurrent illnesses or structural abnormality that could account for the CBS syndrome
  3. * Subjects will be excluded if they have a mutation in the progranulin gene
  4. * Subjects will excluded if they have received anti-Aβ therapy
  5. * Women who are pregnant will be excluded
  6. * Subjects will be excluded if they are actively taking daily anti-inflammatory medications (NSAIDs, corticosteriods, etc)
  7. * Subjects will be excluded if they have generalized inflammatory condition and treatment with immunosuppressive, corticoid/glucocorticoid, steroidal or non-steroidal anti-inflammatory medication within 2 weeks of scanning

Contacts and Locations

Study Contact

Megan J Meyer, M.B.A.
CONTACT
507-293-1164
meyer.megan6@mayo.edu
Sarah M Boland, CCRP
CONTACT
507284-3863
boland.sarah@mayo.edu

Principal Investigator

Jennifer Whitwell, Ph.D.
PRINCIPAL_INVESTIGATOR
Mayo Clinic

Study Locations (Sites)

Mayo Clinic
Rochester, Minnesota, 55905
United States

Collaborators and Investigators

Sponsor: Jennifer Whitwell

  • Jennifer Whitwell, Ph.D., PRINCIPAL_INVESTIGATOR, Mayo Clinic

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-06-01
Study Completion Date2031-03-30

Study Record Updates

Study Start Date2025-06-01
Study Completion Date2031-03-30

Terms related to this study

Keywords Provided by Researchers

  • neurodegeneration
  • neurodegenerative disease
  • cbs
  • cbd
  • corticobasal syndrome
  • corticobasal degeneration

Additional Relevant MeSH Terms

  • Cortico Basal Degeneration
  • Corticobasal Syndrome
  • Corticobasal Syndrome(CBS)
  • Corticobasal Degeneration
  • Corticobasal Degeneration (CBD)
  • Corticobasal Syndrome (CBS)